Raymond James Financial Inc. Makes New Investment in BioNTech SE (NASDAQ:BNTX)

Raymond James Financial Inc. purchased a new position in shares of BioNTech SE (NASDAQ:BNTX - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 5,122 shares of the company's stock, valued at approximately $584,000.

Several other hedge funds have also made changes to their positions in the stock. Jones Financial Companies Lllp grew its position in BioNTech by 110.3% in the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock worth $53,000 after purchasing an additional 246 shares during the last quarter. Quintet Private Bank Europe S.A. grew its stake in shares of BioNTech by 823.5% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock worth $88,000 after purchasing an additional 700 shares in the last quarter. Allianz SE acquired a new position in shares of BioNTech during the fourth quarter valued at $90,000. GAMMA Investing LLC raised its stake in shares of BioNTech by 48.2% during the fourth quarter. GAMMA Investing LLC now owns 923 shares of the company's stock valued at $105,000 after purchasing an additional 300 shares in the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. acquired a new stake in BioNTech in the fourth quarter worth about $137,000. Institutional investors own 15.52% of the company's stock.

BioNTech Stock Performance

BNTX stock traded up $3.93 during midday trading on Monday, hitting $96.70. 484,883 shares of the company traded hands, compared to its average volume of 921,678. BioNTech SE has a twelve month low of $76.53 and a twelve month high of $131.49. The stock has a market capitalization of $23.21 billion, a price-to-earnings ratio of -46.04 and a beta of 1.35. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The business has a 50 day simple moving average of $98.79 and a 200-day simple moving average of $109.48.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.38 by $0.70. The business had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. BioNTech's revenue was down 19.5% compared to the same quarter last year. During the same period last year, the business posted $1.90 EPS. As a group, equities research analysts predict that BioNTech SE will post -3.88 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Canaccord Genuity Group reiterated a "buy" rating and set a $171.44 price target on shares of BioNTech in a research report on Tuesday, March 11th. Citigroup reissued a "buy" rating and issued a $140.00 price target (down from $145.00) on shares of BioNTech in a report on Tuesday, May 6th. BMO Capital Markets lifted their price objective on shares of BioNTech from $130.00 to $143.00 and gave the stock an "outperform" rating in a research note on Tuesday, March 11th. HC Wainwright cut their target price on shares of BioNTech from $150.00 to $145.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Finally, Morgan Stanley decreased their price target on shares of BioNTech from $140.00 to $132.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 6th. Three analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $142.73.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.